Tekton achieved an average of 172% enrollment across three sites, enrolling more than 30 patients in a recent Type 1 Diabetes clinical trial.
Clinical trials are essential to advancing medicine, bringing new therapies from discovery to approval. Traditionally, these trials have been centered in academic institutions and large hospitals—but embedded research site networks like Tekton help make trials accessible within community-based settings, where patients are being treated every day. As a trusted partner in clinical research, Tekton makes … Read more
Initial Collaboration Launches at Yukon, OK Site Austin, TX – July 1, 2025 – Tekton Research is proud to announce a new strategic partnership with Summit Clinical Research, a leading Integrated Research Organization focused on solving the challenges of MASH/NASH clinical trials. The collaboration marks Tekton’s entry into MASH (Metabolic dysfunction-associated steatohepatitis) research, further expanding … Read more
In today’s healthcare landscape, health literacy is more than a buzzword—it’s a foundational element for equitable, ethical, and effective clinical research. But what does health literacy really mean, and why is it so vital in the research setting? Defining Health Literacy Health literacy refers to a person’s ability to access, understand, and use information to … Read more
Tekton reached 240% of enrollment goals, enrolling 12 patients in a CGM study for pregnant women with diabetes.
Tekton averaged 172% enrollment across three sites, enrolling 30+ patients in a Type 1 Diabetes clinical trial.
Tekton Research averaged a one-day turnaround from site activation to first patient visit across seven sites in a recent Phase 3 norovirus vaccine trial.
Each year on May 20, we pause to honor Clinical Trials Day–a global recognition of the people, partnerships and progress that make clinical research possible. This day marks the anniversary of the first randomized clinical trial, conducted in 1747 by James Lind, and serves as a moment to reflect on how far we’ve come–and where … Read more
Tekton Research achieved an average of one day from site activation to first patient visit across seven sites in a Phase 3 norovirus vaccine trial.
Tekton achieved an average of 172% enrollment across seven sites, enrolling more than 720 patients in a 2024 Global Phase 3 vaccine clinical trial.